Company Description
TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets.
The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease.
It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression.
The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2).
TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024.
The company was founded in 2014 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Ian Rhodes CPA |
Contact Details
Address: 1185 Avenue of the Americas, Suite 249 New York, New York 10036 United States | |
| Phone | 856 848 8698 |
| Website | tnfpharma.com |
Stock Details
| Ticker Symbol | TNFA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001321834 |
| CUSIP Number | 62856X201 |
| ISIN Number | US62856X2018 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mitchell Glass M.D. | President, Chief Medical Officer and Director |
| Ian Rhodes CPA | Interim Chief Financial Officer |
| Robert Schatz | Investor Relations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 6, 2025 | 8-K | Current Report |
| May 19, 2025 | DEFR14A | Filing |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 9, 2025 | PRER14A | Filing |
| May 9, 2025 | 8-K | Current Report |
| Apr 21, 2025 | ARS | Filing |
| Apr 21, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 11, 2025 | 8-K | Current Report |
| Apr 11, 2025 | 10-K | Annual Report |